TITAN PHARMACEUTICALS INC: auditor change — Titan Pharmaceuticals appoints new CEO Chay Weei Jye and changes auditor to Enrome LLP

TITAN PHARMACEUTICALS INC

Appointed Chay Weei Jye as CEO effective Dec 2, 2024; previously CTO of Zchwantech.
Audit committee selected Enrome LLP as independent auditor for FY 2024, subject to engagement letter.
Neither company nor anyone on its behalf consulted Enrome on accounting principles or disagreements prior to engagement.
Mr. Chay, age 52, holds a Bachelor of Computer Science from Universiti Putra Malaysia.
No family relationships or arrangements with other persons in selection; no reportable events with prior auditor.

item 4.01 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.95

TITAN PHARMACEUTICALS INC engaged Enrome LLP as its auditor.

Action: engagement
Auditor: Enrome LLP

Exact text from the filing

The Audit Committee of Titan Pharmaceuticals, Inc. (the "Company") recently completed a selection process to determine the Company's independent registered public accounting firm. As a result of this process, the Audit Committee approved the appointment of Enrome LLP ("Enrome") as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024, subject to satisfactory completion of standard engagement acceptance procedures, and the Company entered into an engagement letter with Enrome on December 3, 2024.

View on SEC.gov

Browse all auditor changes →

Source: SEC EDGAR

accession 0001829126-24-008141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.